Science-Based Thinking Promises Global Progress On Biosimilars
Samsung Bioepis’ Gillian Woollett Discusses Latest Regulatory Developments
Executive Summary
A science-based approach to biosimilars, exemplified by the latest statement from European regulators, makes further progress on biosimilars just a matter of time, according to Gillian Woollett, vice president and head of regulatory strategy and policy at Samsung Bioepis.
You may also be interested in...
Generics Bulletin Editor’s Picks For Q4 2022
Looking back over the fourth quarter of 2022, Generics Bulletin executive editor Dave Wallace picks out highlights from October to December that include a leadership change for one of the top industry players, some key developments for biosimilars and the announcement of the winners of our annual awards.
Joined-Up Approach Must Underpin European Biosimilar Procurement
A more joined-up approach is needed on European procurement if the biosimilars market is to remain sustainable in the face of pricing and cost pressures, according to a discussion by industry stakeholders at Medicines for Europe’s 18th Biosimilar Medicines Conference.
Streamlined European Pathway Needed For Biosimilars To Hit Smaller Targets
A more streamlined European regulatory pathway for biosimilars – potentially removing the requirement for confirmatory efficacy trials – is needed for the industry to be able to feasibly offer competition to smaller-value biologic brands, heard delegates to Medicines for Europe’s 18th Biosimilar Medicines Conference.